dndn

ùìåí ìëåìí äðééø ðåâò á5 ãåìàø äàí ùååä ëðéñä ôä? îä ìåç äæîðéí äöôåé
ìâáé ðñéåï ðåñó ì÷áìú äàéùåø äîåï úåãä. __._,_.___. Messages in this
topic (1) Reply (via web post) | Start a new topic. Messages | Files |
Photos | Polls | Members | ...
ùìåí ìëåìí äðééø ðåâò á5 ãåìàø äàí ùååä
ëðéñä ôä? îä ìåç äæîðéí äöôåé ìâáé ðñéåï ðåñó ì÷áìú äàéùåø äîåï úåãä.
__._,_.___. Messages in this topic (1) Reply (via web post) | Start a
new topic. Messages | Files | Photos | Polls | Members | ...
Congress
asking for info on FDA approval process citing potential ethics
problems in review panel. DNDN has been complaining that members of
the review panel were biased, on the take from other competitors. DNDN
could go above $9 short ...
Congress asking for info on FDA approval
process citing potential ethics problems in review panel. DNDN has
been complaining that members of the review panel were biased, on the
take from other competitors. DNDN could go above $9 short ...
US Reps.
Dan Burton, R-Ind., Mike Michaud, D-Maine, and Tim Ryan, D-Ohio,
requested today that the Congress investigate the Food and Drug
Administration's (FDA's) dubious decision to indefinitely delay the
introductio.
Buying Dendreon (DNDN) at $8.3.
Congress asking for info
on FDA approval process citing potential ethics problems in review
panel. DNDN has been complaining that members of the review panel were
biased, on the take from other competitors. DNDN could go above $9
short ...
Bounce back.
Premarket losers: NOVL, NBIX, BDK, TIER, CHINA,
BBL, LIFC, ACGY, GRMN, CPSL, DNDN, AMZN, ZQK, WCI, ACH, BHP, and XTEX.
Today will provide us with some sense on how motivated the sellers are
amid signs of stagflation. For the time being, ...
Congress asking for
info on FDA approval process citing potential ethics problems in
review panel. DNDN has been complaining that members of the review
panel were biased, on the take from other competitors. DNDN could go
above $9 short ...
Bounce back.
Dendreon Corporation (DNDN) traded up
24% on Provenge probe request. Najarian says congressional members
think there was some funny business when Provenge wasn't approved.
Freddie Mac (FRE) traded up 7% on no news. ...
Also, if you are
playing DNDN for the trade… it currently appears overbought, and
hitting the horizontal resistance. An easing on some of the position
should take place, and buy back on a retreat.
Congress asking for info
on FDA approval process citing potential ethics problems in review
panel. DNDN has been complaining that members of the review panel were
biased, on the take from other competitors. DNDN could go above $9
short ...
Also, if you are playing DNDN for the trade… it currently
appears overbought, and hitting the horizontal resistance. An easing
on some of the position should take place, and buy back on a
retreat.